Latest news

Vor Bio changes its priorities & Novo Nordisk Foundation injects €736M in European biotech

Vor Bio changes its priorities & Novo Nordisk Foundation injects €736M in European biotech

Joachim Eeckhout, +1
Caldera raised $112M to target IBD & Cyprium's Menkes disease drug get approved

Caldera raised $112M to target IBD & Cyprium's Menkes disease drug get approved

Joachim Eeckhout, +1
AbbVie kicks off JPM26 with a $5.6B deal & Novartis bets $1.7B brain-shuttle tech

AbbVie kicks off JPM26 with a $5.6B deal & Novartis bets $1.7B brain-shuttle tech

Joachim Eeckhout, +1
Aktis starts 2026 with a $318M IPO & Aurora raises $16M for CRISPR-gene editing

Aktis starts 2026 with a $318M IPO & Aurora raises $16M for CRISPR-gene editing

Joachim Eeckhout, +1
Lily buys Ventyx for $1.2B & Epibiologics raises $107M for its protein degraders

Lily buys Ventyx for $1.2B & Epibiologics raises $107M for its protein degraders

Joachim Eeckhout, +1
Amgen taps into Disco Pharma's pipeline & GSK/Ionis have a 'functional cure' for hepatitis B

Amgen taps into Disco Pharma's pipeline & GSK/Ionis have a 'functional cure' for hepatitis B

Joachim Eeckhout, +1
Amgen buys Dark Blue's protein degraders & Alumis' psoriasis pill shows big promise

Amgen buys Dark Blue's protein degraders & Alumis' psoriasis pill shows big promise

Joachim Eeckhout, +1
Zenas drug trial success fails to impress Wall Street, shares crash 55%

Zenas drug trial success fails to impress Wall Street, shares crash 55%

Joachim Eeckhout, +1
The first new motion sickness drug since 1979 & Genmab's pipeline update

The first new motion sickness drug since 1979 & Genmab's pipeline update

Joachim Eeckhout, +1
Takeda’s $4B psoriasis pill shows blockbuster promise & DBV's patch puts peanuts back on the menu

Takeda’s $4B psoriasis pill shows blockbuster promise & DBV's patch puts peanuts back on the menu

Joachim Eeckhout, +1
Ambros launches with $125M for non-opioid drugs & the EU proposes Biotech Act I

Ambros launches with $125M for non-opioid drugs & the EU proposes Biotech Act I

Joachim Eeckhout, +1
Yarrow buys a Chinese thyroid drug for $1.37B & Aviceda’s lead eye drug misses key trial

Yarrow buys a Chinese thyroid drug for $1.37B & Aviceda’s lead eye drug misses key trial

Joachim Eeckhout, +1
FirstBack
12345678
Next Last